Geron Corp. is set to receive $25 million from the California Institute for Regenerative Medicine to support the clinical work on its stem-cell therapy for spinal cord injury. The money is a loan with repayment contingent on product success.
Molecular Partners AG is set to receive $45 million upfront from Allergan Inc for the exclusive global rights to a therapeutic protein in Phase 2 development for the treatment of retinal diseases. The molecule targets VEGF-A.
Oxford BioMedica Plc, a developer of gene-based medicines and cancer vaccines, has expanded a licensing agreement with Pfizer Inc giving the US multinational non-exclusive rights to its antibody technology for diagnostic use.
ProFibrix BV of the Netherlands, which is developing products to promote hemostasis after surgery, has completed a follow-on Series B financing with the support of new venture capital investors from Luxembourg and the Netherlands.
Ipsen SA, reported a 7.5% rise in group drug sales to €277.3 million in the first 2011 quarter. At constant exchanges rates the gain was 6.3%.
Wilex AG is to receive $19 million upfront as part of a licensing deal with Prometheus Laboratories Inc giving the San Diego-based company exclusive US commercialisation rights to its cancer antibody, Rencarex (girentuximab).
It was an auspicious moment to start a conference. Deborah Harland, partner of SR One, announced at the start of the UK BioTrinity conference on 13 April 2011, that the corporate venture arm of GlaxoSmithKline Plc, had just led a €15 million fundraising for the Austrian antibody company, F-Star GmbH.
Silence Therapeutics Plc is proposing to raise up to £5.5 million through the issue of new shares to institutional investors and directors, and a possible additional £1 million in an open offer, which together would support its RNAi drug development platform.
Oxford Nanopore Technologies Ltd announced that it has raised £25 million through a share placement with new and existing investors to support the further development of its DNA sequencing and other technologies.
Novartis generated $3.1 billion in net sales from recently launched products in the 2011 first quarter, a period that was otherwise marked by a flat operating income and a decline in the company’s operating margin.